# Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

> **NCT02579811** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT02579811
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-30
- **Primary completion:** 2019-08-21
- **Final completion:** 2023-06-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579811, "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02579811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*